mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2022-5-75-81mrj-1350Research ArticleОБЗОРЫREVIEWSИнфекции и системные васкулитыInfections and systemic vasculitishttps://orcid.org/0000-0001-7091-2054БеловБ. С.BelovB. S.

Борис Сергеевич Белов

115522, Москва, Каширское шоссе, 34А

Boris S. Belov

34A, Kashirskoe Shosse, Moscow 115522

belovbor@yandex.ruhttps://orcid.org/0000-0002-4846-5531ЕгороваО. Н.EgorovaO. N.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0001-9933-5350ТарасоваГ. М.TarasovaG. M.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0003-4327-6720МуравьеваН. В.MuravievaN. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2022191020221657581Copyright © Белов Б.С., Егорова О.Н., Тарасова Г.М., Муравьева Н.В., 20222022Белов Б.С., Егорова О.Н., Тарасова Г.М., Муравьева Н.В.Belov B.S., Egorova O.N., Tarasova G.M., Muravieva N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1350

Инфекции и системные васкулиты (СВ) характеризуются взаимным влиянием, что повышает риск возникновения, усугубляет течение и исход заболевания. В обзоре рассматриваются вопросы, касающиеся как триггерной роли инфекций в развитии СВ, так и коморбидных инфекций (КИ), осложняющих течение заболевания. Распознавание инфекционной этиологии СВ имеет большое значение, поскольку требует всестороннего обследования и при необходимости раннего и полноценного этиотропного лечения. Поскольку СВ per se и применение как индукционной, так и поддерживающей иммуносупрессивной терапии являются значимыми факторами риска вторичных КИ, особое внимание необходимо уделять предупреждению последних, включая вакцинопрофилактику, в первую очередь против гриппа и пневмококковой инфекции.

Infections and systemic vasculitis (SV) are characterized by mutual influence, which increases the risk of occurrence, aggravates the course and outcome of the disease. The review considers the issues related to both the trigger role of infections in the development of SV and comorbid infections (CI) that complicate the course of the disease. Recognition of the infectious etiology of SV is of great importance, since it requires a comprehensive examination and, if necessary, early and complete etiotropic treatment. Since SV per se and the use of both induction and maintenance immunosuppressive therapy are significant risk factors for secondary CIs, special attention should be paid to the prevention of the latter, including vaccination, primarily against influenza and pneumococcal infections.

системные васкулитываскулитыассоциированные с антинейтрофильными цитоплазматическими антителамикоморбидные инфекциипневмоцистная пневмонияпрофилактикаsystemic vasculitisvasculitis associated with antineutrophil cytoplasmic antibodiescomorbid infectionspneumocystis pneumoniapreventionReferencesНасонов ЕЛ, Баранов АА, Шилкина НП. Васкулиты и васкулопатии. Ярославль: Верхняя Волга; 1999. 616 с.Nasonov EL, Baranov AA, Shilkina NP. Vaskulity i vaskulopatii [Vasculitis and vasculopathy]. Yaroslavl': Verkhnyaya Volga; 1999. 616 p.Theofilis P, Vordoni A, Koukoulaki M, et al. Overview of infections as an etiologic factor and complication in patients with vasculitides. Rheumatol Int. 2022 May;42(5): 759-70. doi: 10.1007/s00296-022-05100-9. Epub 2022 Feb 14.Theofilis P, Vordoni A, Koukoulaki M, et al. Overview of infections as an etiologic factor and complication in patients with vasculitides. Rheumatol Int. 2022 May;42(5): 759-70. doi: 10.1007/s00296-022-05100-9. Epub 2022 Feb 14.Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996 Jul 4;335(1):16-20. doi: 10.1056/NEJM199607043350103.Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996 Jul 4;335(1):16-20. doi: 10.1056/NEJM199607043350103.Monti S, Delvino P, Riboli M, et al. The role of trimethoprim/sulfametoxazole in reducing relapses and risk of infections in ANCA-associated vasculitis: a meta-analysis. Rheumatology (Oxford). 2021 Aug 2;60(8): 3553-64. doi: 10.1093/rheumatology/keab267.Monti S, Delvino P, Riboli M, et al. The role of trimethoprim/sulfametoxazole in reducing relapses and risk of infections in ANCA-associated vasculitis: a meta-analysis. Rheumatology (Oxford). 2021 Aug 2;60(8): 3553-64. doi: 10.1093/rheumatology/keab267.Van Gool IC, Kers J, Bakker JA, et al. Antineutrophil cytoplasmic antibodies in infective endocarditis: a case report and systematic review of the literature. Clin Rheumatol. 2022 Jun 23. doi: 10.1007/s10067-022-06240-w. Online ahead of print.Van Gool IC, Kers J, Bakker JA, et al. Antineutrophil cytoplasmic antibodies in infective endocarditis: a case report and systematic review of the literature. Clin Rheumatol. 2022 Jun 23. doi: 10.1007/s10067-022-06240-w. Online ahead of print.Huan G, Yang G, Xiao-Yu Q, et al. Antineutrophil cytoplasmic antibodies in Chinese patients with tuberculosis. Rev Soc Bras Med Trop. 2018 Jul-Aug;51(4):475-8. doi: 10.1590/0037-8682-0400-2017.Huan G, Yang G, Xiao-Yu Q, et al. Antineutrophil cytoplasmic antibodies in Chinese patients with tuberculosis. Rev Soc Bras Med Trop. 2018 Jul-Aug;51(4):475-8. doi: 10.1590/0037-8682-0400-2017.Choi H, Park YB, Song J, Lee SW. Unclassifiable repeated antineutrophil cytoplasmic antibody (ANCA) positivity in diseases other than ANCA-associated vasculitis. Z Rheumatol. 2021 Apr 27. doi: 10.1007/s00393-021-00998-1. Online ahead of print.Choi H, Park YB, Song J, Lee SW. Unclassifiable repeated antineutrophil cytoplasmic antibody (ANCA) positivity in diseases other than ANCA-associated vasculitis. Z Rheumatol. 2021 Apr 27. doi: 10.1007/s00393-021-00998-1. Online ahead of print.Söderberg D, Segelmark M. Neutrophil Extracellular Traps in ANCA-Associated Vasculitis. Front Immunol. 2016 Jun 30;7:256. doi: 10.3389/fimmu.2016.00256.Söderberg D, Segelmark M. Neutrophil Extracellular Traps in ANCA-Associated Vasculitis. Front Immunol. 2016 Jun 30;7:256. doi: 10.3389/fimmu.2016.00256.Xiao H, Hu P, Falk RJ, Jennette JC. Overview of the Pathogenesis of ANCA-Associated Vasculitis. Kidney Dis (Basel). 2016 Mar;1(4): 205-15. doi: 10.1159/000442323. Epub 2015 Dec 3.Xiao H, Hu P, Falk RJ, Jennette JC. Overview of the Pathogenesis of ANCA-Associated Vasculitis. Kidney Dis (Basel). 2016 Mar;1(4): 205-15. doi: 10.1159/000442323. Epub 2015 Dec 3.Lizarraga KJ, Florindez JA, Daftarian P, et al. Anti-GBM disease and ANCA during dengue infection. Clin Nephrol. 2015 Feb; 83(2):104-10. doi: 10.5414/CN108217.Lizarraga KJ, Florindez JA, Daftarian P, et al. Anti-GBM disease and ANCA during dengue infection. Clin Nephrol. 2015 Feb; 83(2):104-10. doi: 10.5414/CN108217.Asano S, Mizuno S, Okachi S, et al. Antineutrophil Cytoplasmic Antibody-associated Vasculitis Superimposed on Infection-related Glomerulonephritis Secondary to Pulmonary Mycobacterium avium Complex Infection. Intern Med. 2016;55(17):2439-45. doi: 10.2169/internalmedicine.55.6588. Epub 2016 Sep 1.Asano S, Mizuno S, Okachi S, et al. Antineutrophil Cytoplasmic Antibody-associated Vasculitis Superimposed on Infection-related Glomerulonephritis Secondary to Pulmonary Mycobacterium avium Complex Infection. Intern Med. 2016;55(17):2439-45. doi: 10.2169/internalmedicine.55.6588. Epub 2016 Sep 1.Addy C, Doran G, Jones AL, et al. Microscopic polyangiitis secondary to Mycobacterium abscessus in a patient with bronchiectasis: a case report. BMC Pulm Med. 2018 Nov 19;18(1):170. doi: 10.1186/s12890-018-0732-3.Addy C, Doran G, Jones AL, et al. Microscopic polyangiitis secondary to Mycobacterium abscessus in a patient with bronchiectasis: a case report. BMC Pulm Med. 2018 Nov 19;18(1):170. doi: 10.1186/s12890-018-0732-3.Hashimoto S, Aizawa T, Watanabe S, et al. Osteomyelitis-related glomerulonephritis with myeloperoxidase-antineutrophil cytoplasmic antibody positivity. Pediatr Int. 2020 Feb; 62(2):236-8. doi: 10.1111/ped.14080.Hashimoto S, Aizawa T, Watanabe S, et al. Osteomyelitis-related glomerulonephritis with myeloperoxidase-antineutrophil cytoplasmic antibody positivity. Pediatr Int. 2020 Feb; 62(2):236-8. doi: 10.1111/ped.14080.Sugino H, Sawada Y, Nakamura M. IgA Vasculitis: Etiology, Treatment, Biomarkers and Epigenetic Changes. Int J Mol Sci. 2021 Jul 14;22(14):7538. doi: 10.3390/ijms22147538.Sugino H, Sawada Y, Nakamura M. IgA Vasculitis: Etiology, Treatment, Biomarkers and Epigenetic Changes. Int J Mol Sci. 2021 Jul 14;22(14):7538. doi: 10.3390/ijms22147538.Абдурахманов ДТ, Розина ТП, Новиков ПИ. HBV-ассоциированный узелковый полиартериит. Эпидемиология и инфекционные болезни. Актуальные вопросы. 2012;(3):67-71.Abdurakhmanov DT, Rozina TP, Novikov PI. HBV-associated nodular polyarteritis. Epidemiologiya i infektsionnye bolezni. Aktual'nye voprosy. 2012;(3):67-71. (In Russ.).Семенкова ЕН. Системные некротизирующие васкулиты. Москва: Русский врач; 2001. 96 с.Semenkova EN. Sistemnye nekrotiziruyushchie vaskulity [Systemic necrotizing vasculitis]. Moscow: Russkii vrach; 2001. 96 p.Игнатова ТМ, Козловская ЛВ, Гордовская НБ, и др. Криоглобулинемический васкулит, ассоциированный с вирусом гепатита С: 20-летний опыт лечения. Терапевтический архив. 2017:(5):45-62.Ignatova TM, Kozlovskaya LV, Gordovskaya NB, et al. Hepatitis C virus-associated cryoglobulinemic vasculitis. A 20-year experience with treatment. Terapevticheskii arkhiv. 2017: (5):45-62. (In Russ.).Vega LE, Espinoza LR. Vasculitides in HIV Infection. Curr Rheumatol Rep. 2020 Aug 26;22(10):60. doi: 10.1007/s11926-020-00945-0.Vega LE, Espinoza LR. Vasculitides in HIV Infection. Curr Rheumatol Rep. 2020 Aug 26;22(10):60. doi: 10.1007/s11926-020-00945-0.Vega LE, Espinoza LR. Human immunodeficiency virus infection (HIV)-associated rheumatic manifestations in the pre- and post-HAART eras. Clin Rheumatol. 2020 Sep; 39(9):2515-22. doi: 10.1007/s10067-020-05082-8. Epub 2020 Apr 15.Vega LE, Espinoza LR. Human immunodeficiency virus infection (HIV)-associated rheumatic manifestations in the pre- and post-HAART eras. Clin Rheumatol. 2020 Sep; 39(9):2515-22. doi: 10.1007/s10067-020-05082-8. Epub 2020 Apr 15.Giryes S, Bragazzi NL, Bridgewood C, et al. COVID-19 Vasculitis and vasculopathyDistinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells. Semin Immunopathol. 2022 May;44(3):375-90. doi: 10.1007/s00281-022-00928-6. Epub 2022 Apr 12.Giryes S, Bragazzi NL, Bridgewood C, et al. COVID-19 Vasculitis and vasculopathyDistinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells. Semin Immunopathol. 2022 May;44(3):375-90. doi: 10.1007/s00281-022-00928-6. Epub 2022 Apr 12.Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med. 2020 Jun; 46(6):1105-8. doi: 10.1007/s00134-020-06059-6. Epub 2020 Apr 28.Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med. 2020 Jun; 46(6):1105-8. doi: 10.1007/s00134-020-06059-6. Epub 2020 Apr 28.Брегель ЛВ, Костик ММ, Фелль ЛЗ и др. Болезнь Кавасаки и мультисистемный воспалительный синдром при инфекции COVID-19 у детей. Педиатрия им. Г.Н. Сперанского. 2020;(6):209-19.Bregel LV, Kostik MM, Fell LZ, et al. Kawasaki disease and multisystem inflammatory syndrome in children with COVID-19 infection. Pediatriya im. G.N. Speranskogo. 2020; (6):209-19. (In Russ.).Patel P, DeCuir J, Abrams J, et al. Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults: A Systematic Review. JAMA Netw Open. 2021 Sep 1;4(9):e2126456. doi: 10.1001/jamanetworkopen.2021.26456.Patel P, DeCuir J, Abrams J, et al. Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults: A Systematic Review. JAMA Netw Open. 2021 Sep 1;4(9):e2126456. doi: 10.1001/jamanetworkopen.2021.26456.Fabi M, Filice E, Biagi C, et al. Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection in Children: One Year after the Onset of the Pandemic in a High-Incidence Area. Viruses. 2021 Oct 7;13(10): 2022. doi: 10.3390/v13102022.Fabi M, Filice E, Biagi C, et al. Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection in Children: One Year after the Onset of the Pandemic in a High-Incidence Area. Viruses. 2021 Oct 7;13(10): 2022. doi: 10.3390/v13102022.Sollini M, Ciccarelli M, Cecconi M, et al. Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18F]FDG-PET/ CT study. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1460-6. doi: 10.1007/s00259-020-05084-3.Sollini M, Ciccarelli M, Cecconi M, et al. Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18F]FDG-PET/ CT study. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1460-6. doi: 10.1007/s00259-020-05084-3.Morris D, Patel K, Rahimi O, et al. ANCA vasculitis: A manifestation of PostCovid-19 Syndrome. Respir Med Case Rep. 2021;34:101549. doi: 10.1016/j.rmcr.2021.101549. Epub 2021 Nov 11.Morris D, Patel K, Rahimi O, et al. ANCA vasculitis: A manifestation of PostCovid-19 Syndrome. Respir Med Case Rep. 2021;34:101549. doi: 10.1016/j.rmcr.2021.101549. Epub 2021 Nov 11.Cavalli G, Colafrancesco S, De Luca G, et al. Cutaneous vasculitis following COVID-19 vaccination. Lancet Rheumatol. 2021 Nov; 3(11):e743-e744. doi: 10.1016/S2665-9913(21)00309-X.Cavalli G, Colafrancesco S, De Luca G, et al. Cutaneous vasculitis following COVID-19 vaccination. Lancet Rheumatol. 2021 Nov; 3(11):e743-e744. doi: 10.1016/S2665-9913(21)00309-X.Nappi E, De Santis M, Paoletti G, et al. New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine. Vaccines (Basel). 2022 May 3;10(5):716. doi: 10.3390/vaccines10050716.Nappi E, De Santis M, Paoletti G, et al. New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine. Vaccines (Basel). 2022 May 3;10(5):716. doi: 10.3390/vaccines10050716.Al-Yafeai Z, Horn BJM, Terraccaine W, et al. A Case of Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis Post COVID-19 Vaccination. Cureus. 2022 Mar 14;14(3):e23162. doi: 10.7759/cureus.23162.Al-Yafeai Z, Horn BJM, Terraccaine W, et al. A Case of Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis Post COVID-19 Vaccination. Cureus. 2022 Mar 14;14(3):e23162. doi: 10.7759/cureus.23162.Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 2011 Jan;63(1):257-66. doi: 10.1002/art.27763.Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 2011 Jan;63(1):257-66. doi: 10.1002/art.27763.Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum. 2012 Nov;64(11):3770-8. doi: 10.1002/art.34584.Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum. 2012 Nov;64(11):3770-8. doi: 10.1002/art.34584.Charlier C, Henegar C, Launay O, et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis. 2009 May;68(5):658-63. doi: 10.1136/ard.2008.088302.Charlier C, Henegar C, Launay O, et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis. 2009 May;68(5):658-63. doi: 10.1136/ard.2008.088302.Aasarød K, Iversen BM, Hammerstrøm J, et al. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant. 2000 May;15(5): 611-8. doi: 10.1093/ndt/15.5.611.Aasarød K, Iversen BM, Hammerstrøm J, et al. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant. 2000 May;15(5): 611-8. doi: 10.1093/ndt/15.5.611.Bligny D, Mahr A, Toumelin PL, et al. Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum. 2004 Feb 15;51(1):83-91. doi: 10.1002/art.20082.Bligny D, Mahr A, Toumelin PL, et al. Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum. 2004 Feb 15;51(1):83-91. doi: 10.1002/art.20082.Yang L, Xie H, Liu Z, et al. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. BMC Nephrol. 2018 Jun 14;19(1):138. doi: 10.1186/s12882-018-0933-2.Yang L, Xie H, Liu Z, et al. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. BMC Nephrol. 2018 Jun 14;19(1):138. doi: 10.1186/s12882-018-0933-2.Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest. 2015 Mar;45(3):346-68. doi: 10.1111/eci.12410.Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest. 2015 Mar;45(3):346-68. doi: 10.1111/eci.12410.Jung M, Barra L. Rate of infections in severe necrotising vasculitis patients treated with cyclophosphamide induction therapy: a metaanalysis. Clin Exp Rheumatol. 2018 Mar-Apr; 36 Suppl 111(2):129-34.Jung M, Barra L. Rate of infections in severe necrotising vasculitis patients treated with cyclophosphamide induction therapy: a metaanalysis. Clin Exp Rheumatol. 2018 Mar-Apr; 36 Suppl 111(2):129-34.Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133Segelmark L, Flores-Suarez L, Mohammad A. Severe infections in patients with ANCA-associated vasculitis treated with rituximab. Rheumatology (Oxford). 2021 Dec 24;61(1):205-12. doi: 10.1093/rheumatology/keab293.Segelmark L, Flores-Suarez L, Mohammad A. Severe infections in patients with ANCA-associated vasculitis treated with rituximab. Rheumatology (Oxford). 2021 Dec 24;61(1):205-12. doi: 10.1093/rheumatology/keab293.Odler B, Windpessl M, Krall M, et al. The Risk of Severe Infections Following Rituximab Administration in Patients With Autoimmune Kidney Diseases: Austrian ABCDE Registry Analysis. Front Immunol. 2021 Oct 29;12:760708. doi: 10.3389/fimmu.2021.760708. eCollection 2021.Odler B, Windpessl M, Krall M, et al. The Risk of Severe Infections Following Rituximab Administration in Patients With Autoimmune Kidney Diseases: Austrian ABCDE Registry Analysis. Front Immunol. 2021 Oct 29;12:760708. doi: 10.3389/fimmu.2021.760708. eCollection 2021.Lee YH, Song GG. Comparative efficacy and safety of rituximab, mycophenolate, methotrexate, and cyclophosphamide versus azathioprine as maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: A Bayesian network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2022 Feb;60(2):97-105. doi: 10.5414/CP204053.Lee YH, Song GG. Comparative efficacy and safety of rituximab, mycophenolate, methotrexate, and cyclophosphamide versus azathioprine as maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: A Bayesian network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2022 Feb;60(2):97-105. doi: 10.5414/CP204053.Furuta S, Nakagomi D, Kobayashi Y, et al. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial. JAMA. 2021 Jun 1;325(21):2178-87. doi: 10.1001/jama.2021.6615.Furuta S, Nakagomi D, Kobayashi Y, et al. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial. JAMA. 2021 Jun 1;325(21):2178-87. doi: 10.1001/jama.2021.6615.Godeau B, Mainardi JL, Roudot-Thoraval F, et al. Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann Rheum Dis. 1995 Dec; 54(12):991-4.Godeau B, Mainardi JL, Roudot-Thoraval F, et al. Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann Rheum Dis. 1995 Dec; 54(12):991-4.Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with wegener’s granulomatosis. Am J Respir Crit Care Med. 1995 Mar;151 (3 Pt 1):795-9. doi: 10.1164/ajrccm/151.3_Pt_1.795.Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with wegener’s granulomatosis. Am J Respir Crit Care Med. 1995 Mar;151 (3 Pt 1):795-9. doi: 10.1164/ajrccm/151.3_Pt_1.795.Falagas ME, Manta KG, Betsi GI, et al. Infection-related morbidity and mortality in patients with connective tissue diseases: a systemic review. Clin Rheumatol. 2007 May;26(5): 663-70. doi: 10.1007/s10067-006-0441-9. Epub 2006 Dec 21.Falagas ME, Manta KG, Betsi GI, et al. Infection-related morbidity and mortality in patients with connective tissue diseases: a systemic review. Clin Rheumatol. 2007 May;26(5): 663-70. doi: 10.1007/s10067-006-0441-9. Epub 2006 Dec 21.Fillatre P, Decaux O, Jouneau S, et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med. 2014 Dec;127(12):1242.e11- 7. doi: 10.1016/j.amjmed.2014.07.010. Epub 2014 Jul 21.Fillatre P, Decaux O, Jouneau S, et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med. 2014 Dec;127(12):1242.e11- 7. doi: 10.1016/j.amjmed.2014.07.010. Epub 2014 Jul 21.Li J, Huang XM, Fang WG, et al. Pneumocystis carinii pneumonia in patients with connective tissue disease. J Clin Rheumatol. 2006 Jun;12(3):114-7. doi: 10.1097/01.rhu.0000221794.24431.36.Li J, Huang XM, Fang WG, et al. Pneumocystis carinii pneumonia in patients with connective tissue disease. J Clin Rheumatol. 2006 Jun;12(3):114-7. doi: 10.1097/01.rhu.0000221794.24431.36.Zhang Y, Zheng Y. Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases. Rheumatol Int. 2014 Dec; 34(12):1765-71. doi: 10.1007/s00296-014-3073-4. Epub 2014 Jun 20.Zhang Y, Zheng Y. Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases. Rheumatol Int. 2014 Dec; 34(12):1765-71. doi: 10.1007/s00296-014-3073-4. Epub 2014 Jun 20.Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized wegener’s granulomatosis. Arthritis Rheum. 1997 Dec;40(12):2187-98. doi: 10.1002/art.1780401213.Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized wegener’s granulomatosis. Arthritis Rheum. 1997 Dec;40(12):2187-98. doi: 10.1002/art.1780401213.Jones RB, Tervaert JWC, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010 Jul 15;363(3):211-20. doi: 10.1056/NEJMoa0909169.Jones RB, Tervaert JWC, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010 Jul 15;363(3):211-20. doi: 10.1056/NEJMoa0909169.Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013 Aug 1;369(5):417-27. doi: 10.1056/NEJMoa1213277.Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013 Aug 1;369(5):417-27. doi: 10.1056/NEJMoa1213277.Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014 Nov 6;371(19):1771-80. doi: 10.1056/NEJMoa1404231.Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014 Nov 6;371(19):1771-80. doi: 10.1056/NEJMoa1404231.Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/ Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021 Aug;73(8):1366-83. doi: 10.1002/art.41773. Epub 2021 Jul 8.Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/ Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021 Aug;73(8):1366-83. doi: 10.1002/art.41773. Epub 2021 Jul 8.Chung JB, Armstrong K, Schwartz S, et al. Cost-effectiveness of prophylaxis against pneumocystis carinii pneumonia in patients with wegener’s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum. 2000 Aug;43(8):1841-8. doi: 10.1002/1529-0131(200008)43:83.0.CO;2-Q.Chung JB, Armstrong K, Schwartz S, et al. Cost-effectiveness of prophylaxis against pneumocystis carinii pneumonia in patients with wegener’s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum. 2000 Aug;43(8):1841-8. doi: 10.1002/1529-0131(200008)43:83.0.CO;2-Q.Sattui SE, Conway R, Putman MS, et al. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatol. 2021 Dec;3(12):e855-e864. doi: 10.1016/S2665-9913(21)00316-7. Epub 2021 Nov 5.Sattui SE, Conway R, Putman MS, et al. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatol. 2021 Dec;3(12):e855-e864. doi: 10.1016/S2665- 9913(21)00316-7. Epub 2021 Nov 5.Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2022 May;81(5):695-709. doi: 10.1136/annrheumdis-2021-221490. Epub 2021 Dec 31.Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2022 May;81(5):695-709. doi: 10.1136/annrheumdis-2021-221490. Epub 2021 Dec 31.David R, Hanna P, Lee K, Ritchie A. Relapsed ANCA associated vasculitis following Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: A case series of two patients. Nephrology (Carlton). 2022 Jan; 27(1):109-10. doi: 10.1111/nep.13993. Epub 2021 Nov 9.David R, Hanna P, Lee K, Ritchie A. Relapsed ANCA associated vasculitis following Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: A case series of two patients. Nephrology (Carlton). 2022 Jan; 27(1):109-10. doi: 10.1111/nep.13993. Epub 2021 Nov 9.Kondo M, Yamanaka K. Possible HSP reactivation post-COVID-19 vaccination and booster. Clin Case Rep. 2021 Oct 28;9(10): e05032. doi: 10.1002/ccr3.5032. eCollection 2021 Oct.Kondo M, Yamanaka K. Possible HSP reactivation post-COVID-19 vaccination and booster. Clin Case Rep. 2021 Oct 28;9(10): e05032. doi: 10.1002/ccr3.5032. eCollection 2021 Oct.Dharia T, Venkatachalam S, Baker JF, et al. Medication Interruptions and Subsequent Disease Flares During the COVID-19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease. Arthritis Care Res (Hoboken). 2022 May;74(5):733-40. doi: 10.1002/acr.24837.Dharia T, Venkatachalam S, Baker JF, et al. Medication Interruptions and Subsequent Disease Flares During the COVID-19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease. Arthritis Care Res (Hoboken). 2022 May;74(5):733-40. doi: 10.1002/acr.24837.Chen YX, Yu HJ, Zhang W, et al. Analyzing fatal cases of Chinese patients with primary antineutrophil cytoplasmic antibodiesassociated renal vasculitis: a 10-year retrospective study. Kidney Blood Press Res. 2008; 31(5):343-9. doi: 10.1159/000165117. Epub 2008 Oct 23.Chen YX, Yu HJ, Zhang W, et al. Analyzing fatal cases of Chinese patients with primary antineutrophil cytoplasmic antibodiesassociated renal vasculitis: a 10-year retrospective study. Kidney Blood Press Res. 2008; 31(5):343-9. doi: 10.1159/000165117. Epub 2008 Oct 23.Itabashi M, Takei T, Yabuki Y, et al. Clinical outcome and prognosis of anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan. Nephron Clin Pract. 2010;115(1):c21-7. doi: 10.1159/000286346. Epub 2010 Feb 19.Itabashi M, Takei T, Yabuki Y, et al. Clinical outcome and prognosis of anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan. Nephron Clin Pract. 2010;115(1):c21-7. doi: 10.1159/000286346. Epub 2010 Feb 19.Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCAassociated vasculitis. 2011 Mar;70(3):488-94. doi: 10.1136/ard.2010.137778.Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCAassociated vasculitis. 2011 Mar;70(3):488-94. doi: 10.1136/ard.2010.137778.

The authors declare that there are no conflicts of interest present.